Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial-Reference-Cited by-同舟云学术

Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial

Published:2021-04-15 Issue:6 Volume:38 Page:481-491
ISSN:1170-229X
Container-title:Drugs & Aging
language:en
Short-container-title:Drugs Aging

Author:

Salvadori Emilia,Poggesi Anna,Donnini Ida,Rinnoci Valentina,Chiti Guido,Squitieri Martina,Tudisco Laura,Fierini Fabio,Melone Anna,Pescini Francesca,Pantoni Leonardo^ORCID

Funder

Università degli Studi di Milano

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Geriatrics and Gerontology

Link

https://link.springer.com/content/pdf/10.1007/s40266-021-00852-8.pdf

Reference45 articles.

1. O’Brien JT, Erkinjuntti T, Reisberg B, et al. Vascular cognitive impairment. Lancet Neurol. 2003;2(2):89–98. https://doi.org/10.1016/s1474-4422(03)00305-3.

2. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689–701. https://doi.org/10.1016/S1474-4422(10)70104-6.

3. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822–38. https://doi.org/10.1016/S1474-4422(13)70124-8.